Jamie Fletcher

Conjoint Senior Lecturer

Research outline

I am a translational researcher based at the Children’s Cancer Institute, where I lead a team of postdoctoral researchers and students focused on the childhood solid tumour neuroblastoma. Children with high-risk neuroblastoma frequently relapse with incurable, drug resistant disease, resulting in long-term survival rates below 50%. We seek to understand the biology of neuroblastoma and to improve patient survival rates through:

  • Identifying molecular mechanisms underlying drug resistance
  • Developing small molecule inhibitors targeting drug resistance mechanisms, with particular focus on multidrug resistance proteins
  • Developing improved pre-clinical testing models for high-risk neuroblastoma, including patient-derived xenograft (PDX) models and models of metastatic disease
  • Modelling personalised medicine strategies, including molecular profiling and ex vivo drug sensitivity screening

My team applies high-throughput drug screening, genomic analysis, mouse models, cell biology and tissue-culture based approaches to the study of drug resistance mechanisms, personalised medicine and new drug development in high-risk neuroblastoma. Our high-risk neuroblastoma research is published in leading journals, including JNCI, Cancer Res, Oncogene, Eur J Cancer, Nature Reviews Cancer and Science Translational Medicine.

Sample publications

Kamili A, Gifford AJ, Li N, Mayoh C, Chow SO, Failes TW, Eden GL, Cadiz R, Xie J, Lukeis RE, Norris MD, Haber M, McCowage GB, Arndt GM, Trahair TN, Fletcher JI (2020) Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. British Journal of Cancer Jan 10, 2020. doi: 10.1038/s41416-019-0682-4.

Koach J, Holien JK, …24 authors…Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer Research 79(21):5652-5667.

Huynh T, Murray J, Flemming CL, Kamili A, Hofmann U, Cheung L, Roundhill EA, Yu DMT, Webber HT, Schwab M, Henderson MJ, Haber M, Norris MD, Fletcher JI. (2019) CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. Biochemical Pharmacology 172:113770.

Gana CC, Hanssen KM, Yu DM, Flemming CL, Wheatley MS, Conseil G, Cole SPC, Norris MD, Haber M, Fletcher JI (2019) MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology 168:237-248.

Gamble LD…24 authors…Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M (2019) Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine 11 (477), eaau1099.

Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD. (2018) Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nature Reviews Cancer 18(6):389-400

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI (2017) Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumor growth and sensitizes to irinotecan in vivo European Journal of Cancer 83:132-141.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers (2017) Cancer Research 77(4):971-981

O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. (2016) MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin Cancer Research 76(12):3604-17.

Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, *Fletcher JI, *Ashton LJ (2015) MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget 6:15510-23.

Cheung L, Yu DM, Neiron Z, Failes TW, Arndt GM, Fletcher JI (2015) Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. Biochemical Pharmacology 93:380-8.

Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, Conseil G, Tivnan A, Polinsky A, Gudkov AV, Munoz MA, Vishvanath A, Cooper DM, Henderson MJ, Cole SP, Fletcher JI, Haber M, Norris MD. (2014) High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology 91:97-108.

Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, London WB, Marshall GM, Norris MD, Perini G, Haber M (2012) N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. Cancer Research 72(4):845-853.

Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 10, 147-56.

Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DCS, Adams JM (2008) Apoptosis is triggered when pro-survival Bcl-2 proteins cannot restrain Bax. Proceeding of the National Academy of Sciences USA 105, 18081-18087.

Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859.

Publications

Journal articles
add
Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, vol. 172, http://dx.doi.org/10.1016/j.bcp.2019.113770
2020
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T, 2020, 'Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma', International Journal of Cancer, http://dx.doi.org/10.1002/ijc.32936
2020
Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-019-0682-4
2020
Le Grand M; Kimpton K; Gana CC; Valli E; Fletcher JI; Kavallaris M, 2020, 'Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma', ACS Pharmacology & Translational Science, vol. 3, pp. 148 - 160, http://dx.doi.org/10.1021/acsptsci.9b00085
2020
Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0
2020
Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, http://dx.doi.org/10.1038/s41388-020-1235-2
2020
Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, vol. 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112
2019
Boutros R; Catchpoole D; Collins K; Cross S; Downie P; Drinkwater C; Fletcher J; Gottardo N; Hunter S; Kirby M; Ludlow L; MacNish M; Maybury M; Moore A; Morrin H; Purdy S; Revesz T; Saffery R; Strong R; Trahair T; Wood A; Byrne J, 2019, 'The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network', Biopreservation and Biobanking, vol. 17, pp. 95 - 97, http://dx.doi.org/10.1089/bio.2019.0013
2019
Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, vol. 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009
2019
Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, vol. 11, http://dx.doi.org/10.1126/scitranslmed.aau1099
2019
Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, vol. 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x
2018
Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, vol. 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024
2017
Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, vol. 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906
2017
Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675
2016
Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004
2016
Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, vol. 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001
2016
O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, vol. 76, pp. 3604 - 3617, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879
2016
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, vol. 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732
2015
Cheung L; Yu DMT; Neiron Z; Failes TW; Arndt GM; Fletcher JI, 2015, 'Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen', Biochemical Pharmacology, vol. 93, pp. 380 - 388, http://dx.doi.org/10.1016/j.bcp.2014.11.006
2015
Fletcher J; Roundhill E; Haber M; Norris M, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52
2014
Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M, 2014, 'RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model', Oncogene, vol. 33, pp. 882 - 890, http://dx.doi.org/10.1038/onc.2013.11
2014
Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, vol. 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023
2014
Fletcher JI; Haber M; Henderson M; Norris MD, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, edn. Pediatric Cancer-Diagnosis Therapy and Prognosis, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11
2012
Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M, 2012, 'N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma', Cancer Research, vol. 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885
2012
Henderson M; Haber M; Porro A; Munoz M; Xue C; Murray JE; Flemming C; Smith J; Fletcher JI; Gherardi S; Kwek C; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD, 2011, 'ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux', Journal of the National Cancer Institute, vol. 103, pp. 1236 - 1251, http://dx.doi.org/10.1093/jcni/djr256
2011
Fletcher JI; Haber M; Henderson M; Norris MD, 2010, 'ABC transporters in cancer: more than just drug efflux pumps', Nature Reviews Cancer, vol. 10, pp. 147 - 156, http://dx.doi.org/10.1038/nrc2789
2010
Kvansakul M; Wei AH; Fletcher JI; Willis SN; Chen L; Roberts AW; Huang DCS; Colman PM, 2010, 'Structural basis for apoptosis inhibition by Epstein-Barr virus bhrf1', PLoS Pathogens, vol. 6, http://dx.doi.org/10.1371/journal.ppat.1001236
2010
Branson KM; Mertens HDT; Swarbrick JD; Fletcher JI; Kedzierski L; Gayler KR; Gooley PR; Smith BJ, 2009, 'Discovery of Inhibitors of Lupin Diadenosine 5 ',5 '''-P-1,P-4-Tetraphosphate Hydrolase by Virtual Screening', BIOCHEMISTRY, vol. 48, pp. 7614 - 7620, http://dx.doi.org/10.1021/bi900813x
2009
Fletcher JI; Meusburger S; Hawkins CJ; Riglar DT; Lee EF; Fairlie WD; Huang DCS; Adams JM, 2008, 'Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 18081 - 18087, http://dx.doi.org/10.1073/pnas.0808691105
2008
Fletcher JI; Huang DCS, 2008, 'Controlling the cell death mediators Bax and Bak - Puzzles and conundrums', CELL CYCLE, vol. 7, pp. 39 - 44, http://dx.doi.org/10.4161/cc.7.1.5178
2008
Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DCS, 2007, 'Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak', SCIENCE, vol. 315, pp. 856 - 859, http://dx.doi.org/10.1126/science.1133289
2007
Mason KD; Carpinelli MR; Fletcher JI; Collinge JE; Hilton AA; Ellis S; Kelly PN; Ekert PG; Metcalf D; Roberts AW; Huang DCS; Kile BT, 2007, 'Programmed Anuclear Cell Death Delimits Platelet Life Span', Cell, vol. 128, pp. 1173 - 1186, http://dx.doi.org/10.1016/j.cell.2007.01.037
2007
Fletcher JI; Huang DCS, 2006, 'BH3-only proteins: orchestrating cell death', CELL DEATH AND DIFFERENTIATION, vol. 13, pp. 1268 - 1271, http://dx.doi.org/10.1038/sj.cdd.4401995
2006
Willis SN; Chen L; Dewson G; Wei A; Naik E; Fletcher JI; Adams JM; Huang DCS, 2005, 'Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x(L), but not Bcl-2, until displaced by BH3-only proteins', GENES & DEVELOPMENT, vol. 19, pp. 1294 - 1305, http://dx.doi.org/10.1101/gad.1304105
2005
Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DCS, 2005, 'Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function', MOLECULAR CELL, vol. 17, pp. 393 - 403, http://dx.doi.org/10.1016/j.molcel.2004.12.030
2005
Adams JM; Huang DCS; Strasser A; Willis S; Chen L; Wei A; Van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S, 2005, 'Subversion of the Bcl-2 life/death switch in cancer development and therapy', Molecular Approaches to Controlling Cancer, vol. 70, pp. 469 - 477, http://dx.doi.org/10.1101/sqb.2005.70.009
2005
Swarbrick JD; Buyya S; Gunawardana D; Fletcher JI; Branson K; Smith B; Pepe S; McLennan A; Gayler KR; Gooley PR, 2005, 'Letter to the Editor: H-1, C-13, and N-15 resonance assignments of the 17 kDa Ap4A hydrolase from Homo sapiens in the presence and absence of ATP', JOURNAL OF BIOMOLECULAR NMR, vol. 31, pp. 181 - 182, http://dx.doi.org/10.1007/s10858-004-7440-4
2005
Voskoboinik I; Thia MC; Fletcher J; Ciccone A; Browne K; Smyth MJ; Trapani JA, 2005, 'Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain', JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, pp. 8426 - 8434, http://dx.doi.org/10.1074/jbc.M413303200
2005
de Planque MRR; Rijkers DTS; Fletcher JI; Liskamp RMJ; Separovic F, 2004, 'The alpha-M1 segment of the nicotinic acetylcholine receptor exhibits conformational flexibility in a membrane environment', BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, vol. 1665, pp. 40 - 47, http://dx.doi.org/10.1016/j.bbamem.2004.06.021
2004
Fletcher JI; Swarbrick JD; Maksel D; Gayler KR; Gooley PR, 2002, 'The structure of Ap(4)A hydrolase complexed with ATP-MgFx reveals the basis of substrate binding', STRUCTURE, vol. 10, pp. 205 - 213, http://dx.doi.org/10.1016/S0969-2126(02)00696-2
2002
Tedford HW; Fletcher JI; King GF, 2001, 'Functional Significance of the β-Hairpin in the Insecticidal Neurotoxin ω-Atracotoxin-Hv1a', Journal of Biological Chemistry, vol. 276, pp. 26568 - 26576, http://dx.doi.org/10.1074/jbc.M102199200
2001
Fletcher JI; Wang X; Connor M; Christie MJ; King GF; Nicholson GM, 1999, 'Spider toxins: A new group of potassium channel modulators', Perspectives in Drug Discovery and Design, vol. 15-16, pp. 61 - 69, http://dx.doi.org/10.1023/A:1017039418046
1999
Fletcher JI; Dingley AJ; Smith R; Connor M; Christie MJ; King GF, 1999, 'High-resolution solution structure of gurmarin, a sweet-taste- suppressing plant polypeptide', European Journal of Biochemistry, vol. 264, pp. 525 - 533, http://dx.doi.org/10.1046/j.1432-1327.1999.00659.x
1999
Wang XH; Smith R; Fletcher JI; Wilson H; Wood CJ; Howden MEH; King GF, 1999, 'Structure-function studies of ω-atracotoxin, a potent antagonist of insect voltage-gated calcium channels', European Journal of Biochemistry, vol. 264, pp. 488 - 494, http://dx.doi.org/10.1046/j.1432-1327.1999.00646.x
1999
Torres AM; Wang X; Fletcher JI; Alewood D; Alewood PF; Smith R; Simpson RJ; Nicholson GM; Sutherland SK; Gallagher CH; King GF; Kuchel PW, 1999, 'Solution structure of a defensin-like peptide from platypus venom', Biochemical Journal, vol. 341, pp. 785 - 794, http://dx.doi.org/10.1042/0264-6021:3410785
1999